Abstract
The diseases caused by Shiga and cholera toxins account for the loss of millions of lives each year1. Both belong to the clinically significant subset of bacterial AB5 toxins consisting of an enzymatically active A subunit that gains entry to susceptible mammalian cells after oligosaccharide recognition by the B5 homopentamer2,3. Therapies might target the obligatory oligosaccharide–toxin recognition event4, but the low intrinsic affinity of carbohydrate–protein interactions hampers the development of low-molecular-weight inhibitors5. The toxins circumvent low affinity by binding simultaneously to five or more cell-surface carbohydrates6. Here we demonstrate the use of the crystal structure of the B5 subunit of Escherichia coli O157:H7 Shiga-like toxin I (SLT-I) in complex with an analogue of its carbohydrate receptor6 to design an oligovalent, water-soluble carbohydrate ligand (named STARFISH), with subnanomolar inhibitory activity. The in vitro inhibitory activity is 1–10-million-fold higher than that of univalent ligands and is by far the highest molar activity of any inhibitor yet reported for Shiga-like toxins I and II. Crystallography of the STARFISH/Shiga-like toxin I complex explains this activity. Two trisaccharide receptors at the tips of each of five spacer arms simultaneously engage all five B subunits of two toxin molecules.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Holmgren, J. & Svennerholm, A. M. Bacterial enteric infections and vaccine development. Gastroenterology Clinics of North America 21, 283–302 ( 1992).
Merritt, E. A. & Hol, W. G. J. AB5 toxins. Curr. Opin. Struct. Biol. 5, 165–171 (1995).
Lindberg, A. A. et al. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae Type 1. J. Biol. Chem. 262, 1779–1785 ( 1987).
Aronson, M. et al. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl α- D-mannopyranoside. J. Infect. Dis. 139, 329–332 (1979).
Mammen, M., Choi, S.-K. & Whitesides, G. M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37, 2754 (1998 ).
Ling, H. et al. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 37, 1777–1788 (1998).
Karmali, M. A., Steele, B. T., Petric, M. & Lim, C. Sporadic cases of haemolytic-uremic syndrome associated with fecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet i, 619–620 (1983).
Karmali, M. A. et al. The association between idiopathic hemolytic uremic syndrome and infection by Verotoxin-producing Escherichia coli. J. Infect. Dis. 151, 775–782 (1985).
Cimolai, N., Carter, J. E., Morrison, B. J. & Anderson, J. D. Risk factors for the progression of Escherichia coli O 157:H7 enteritis to hemolytic–uremic syndrome. J. Pediatr. 116 , 589–592 (1990).
Boyd, B. & Lingwood, C. Verotoxin receptor glycolipid in human renal tissue. Nephron 51, 207– 210 (1989).
Armstrong, G. D., Fodor, E. & Vanmaele, R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 164, 1160–1167 (1991).
O'Brien, A. D. et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180 , 65–94 (1992).
DeGrandis, S. et al. Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J. Bacteriol. 169, 4313–4319 ( 1987).
Stein, P. E., Boodhoo, A., Tyrrell, G. J., Brunton, J. L. & Read, R. J. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 355, 748–750 (1992).
St. Hilaire, P. M., Boyd, M. K. & Toone, E. J. Interaction of the Shiga-like type 1 B-subunit with its carbohydrate receptor. Biochemistry 33, 14452–14463 (1994).
Nyholm, P. G. et al. Two distinct binding sites for globotriaosyl on verotoxins: identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins. Chem. Biol. 3, 263–275 (1996).
Bast, D. J., Banerjee, L., Clark, C., Read, R. J. & Brunton, J. L. The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit. Mol. Microbiol. 32, 953– 960 (1999).
Shimizu, H., Field, R. A., Homans, S. W. & Donohue-Rolfe, A. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry 31, 11078– 11082 (1998).
Fuchs, G. et al. Pathogenesis of Shigella diarrhea: rabbit intestinal cell microvillus membrane binding site for Shigella toxin. Infect. Immun. 53, 372–377 ( 1986).
Dubber, M. & Lindhorst, T. K. Synthesis of octopus glycosides: core molecules for the construction of glycoclusters and carbohydrate-centered dendrimers. Carbohydr. Res. 310, 35– 41 (1998).
Kitov, P. I., Railton, C. & Bundle, D. R. The synthesis of 16-mercaptohexadecanyl glycosides for biosensor applications. Carbohydr. Res. 307, 361–369 (1998).
Tesh, V. L. et al. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 61, 3392–3402 (1993).
Mulvey, G., Vanmaele, R., Mrazek, M., Cahill, M. & Armstrong, G. D. Affinity purification of Shiga-like toxin I and Shiga-like toxin II. J. Microbiol. Methods 32, 247– 252 (1998).
Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50, 157–163 ( 1994).
Brünger, A. T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905–921 (1998).
Pannu, N. S. & Read, R. J. Improved structure refinement through maximum likelihood. Acta Crystallogr. A 52, 659–668 (1996).
McRee, D. E. XtalView/Xfit—a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125, 156–165 (1999).
Read, R. J. Model phases: probabilities and bias. Methods Enzymol. 277, 110–128 (1997).
Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946 –950 (1991).
Merritt, E. A. & Bacon, D. J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277, 505–524 (1997).
Acknowledgements
Protein used in the crystallographic experiments was a generous gift from J. L. Brunton. This work was supported by grants from the Canadian Bacterial Disease Network and a grant to R.J.R. from the Wellcome Trust (UK). We thank the MRC Laboratory of Molecular Biology in Cambridge for the allocation of resources for diffraction data collection, B. Hazes for assistance in data collection, and K. Hayakawa for technical assistance in growing the crystals.
Author information
Authors and Affiliations
Supplementary information
Supplementary Information
Supplementary Information (PDF 72 kb)
Rights and permissions
About this article
Cite this article
Kitov, P., Sadowska, J., Mulvey, G. et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403, 669–672 (2000). https://doi.org/10.1038/35001095
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/35001095
This article is cited by
-
Critical parameters for design and development of multivalent nanoconstructs: recent trends
Drug Delivery and Translational Research (2022)
-
Designer DNA architecture offers precise and multivalent spatial pattern-recognition for viral sensing and inhibition
Nature Chemistry (2020)
-
Cell-free systems for accelerating glycoprotein expression and biomanufacturing
Journal of Industrial Microbiology and Biotechnology (2020)
-
A cell-free biosynthesis platform for modular construction of protein glycosylation pathways
Nature Communications (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.